Released Nov 6, 2025, after the close
10-Q filed Nov 6, 2025, 37 days after period end · 0001628280-25-050193
Q3 2025 · 10-Q
Revenue$29.38M$29.38M −67.0% vs Q3 2024−24.9% vs Q2 2025
Net Income-$80.76M-$80.76M N/M vs Q3 2024N/M vs Q2 2025
EPS Diluted-$1.45-$1.45 N/M vs Q3 2024N/M vs Q2 2025
Operating Income-$82,305,000N/M
Operating Cash Flowderived-$31,606,000N/M
Free Cash Flowderived-$31,606,000N/M
Margins · derived
Operating margin-280.1%−218.1 pt vs Q3 2024
Net margin-274.9%−211.5 pt vs Q3 2024
What the release said
The release
Same quarter
| Metric | Q3 2025 | Q3 2024 | Q3 2023 | Q3 2022 |
|---|---|---|---|---|
| Revenue | $29.38M | $89.05M | $55.43M | $66.40M |
| Net Income | -$80.76M | -$56.40M | -$302.89M | -$670.13M |
| EPS Diluted | -$1.45 | -$1.08 | -$6.21 | -$0.41 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ginkgo Bioworks Holdings, Inc. · CIK 1830214 · Engraved from SEC EDGAR